Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolism and Excretion of [14C]Lemborexant in Healthy Males
NCT02046213Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2014
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lemborexant in Insomnia, sponsored by Eisai Co., Ltd. Primary endpoints: Pharmacokinetics: Excretion of E2006: urine/feces concentration up to 35 days and Pharmacokinetics: Plasma concentration of E2006/metabolite. Started Feb 2014; status: completed.
02
Drugs
lemborexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT02046213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02046213.